Bionik Laboratories Corp., a robotics company, focuses on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company specializes in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Systems, which include the InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND, an add-on module to be used with the InMotion ARM; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company is also developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; and ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, stroke, and other mobility disabilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone1-416-640-7887
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$990,000.00
Profitability
Miscellaneous
Employees27
Next Earnings Date6/26/2019 (Estimated)
OptionableNot Optionable
Bionik Laboratories (OTCMKTS:BNKL) Frequently Asked Questions
What is Bionik Laboratories' stock symbol?
Bionik Laboratories trades on the OTCMKTS under the ticker symbol "BNKL."
When is Bionik Laboratories' next earnings date?
Has Bionik Laboratories been receiving favorable news coverage?
News stories about BNKL stock have been trending somewhat positive on Wednesday, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bionik Laboratories earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Bionik Laboratories' key competitors?
What other stocks do shareholders of Bionik Laboratories own?
Who are Bionik Laboratories' key executives?
Bionik Laboratories' management team includes the folowing people:
- Dr. Eric Michel Dusseux M.D., MSc, MBA, CEO & Director (Age 51)
- Mr. Michal Prywata, Co-Founder, CTO & Director (Age 28)
- Ms. Leslie N. Markow, Chief Financial Officer (Age 59)
- Mr. William Harris, Marketing Director
- Mr. Renaud Bertrand Maloberti, Chief Commercial Officer (Age 50)
How do I buy shares of Bionik Laboratories?
Shares of BNKL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bionik Laboratories' stock price today?
One share of BNKL stock can currently be purchased for approximately $4.00.
How big of a company is Bionik Laboratories?
Bionik Laboratories has a market capitalization of $9.36 million and generates $990,000.00 in revenue each year. Bionik Laboratories employs 27 workers across the globe.
What is Bionik Laboratories' official website?
How can I contact Bionik Laboratories?
Bionik Laboratories' mailing address is 483 Bay Street N105, Toronto A6, M5G2C9. The company can be reached via phone at 1-416-640-7887 or via email at https://ir.bioniklabs.com.
MarketBeat Community Rating for Bionik Laboratories (OTCMKTS BNKL)
MarketBeat's community ratings are surveys of what our community members think about Bionik Laboratories and other stocks. Vote "Outperform" if you believe BNKL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNKL will underperform the S&P 500 over the long term. You may vote once every thirty days.
